Prevention and cure: The major unmet needs in the management of rheumatoid arthritis - PubMed (original) (raw)
Review
doi: 10.1016/j.jaut.2019.102399. Epub 2019 Dec 31.
Affiliations
- PMID: 31899021
- DOI: 10.1016/j.jaut.2019.102399
Free article
Review
Prevention and cure: The major unmet needs in the management of rheumatoid arthritis
Kulveer Mankia et al. J Autoimmun. 2020 Jun.
Free article
Abstract
The outcome of treatment of patients with rheumatoid arthritis (RA) has qualitatively improved in recent years due to better and earlier treatment approaches, and new drugs. It is now generally accepted that the phenotype of RA is the end-point of a disease continuum. Large retrospective studies have identified anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor in the stored serum of patients, years before the development of clinical RA. Recent data suggest mucosal sites such as the oral mucosa (in particular the periodontium), lung and gut may be the sites where auto-immunity is initiated. The role of bacteria at these sites is reviewed. Much recent work has focussed on the role of high resolution imaging namely ultrasound and magnetic resonance imaging in identifying subclinical inflammation in at-risk individuals with early musculoskeletal symptoms (e.g. arthralgia) but without clinical synovitis. Importantly, the first musculoskeletal site involved is usually not the joint (synovium). Sub-clinical disease predicts the onset of clinical arthritis, and its timing, in symptomatic at-risk individuals. These and other predictive markers will be described. The ability to identify patients at-risk of RA before joint involvement has led to interventions aimed at preventing/delaying disease. Once arthritis occurs, rapid remission is the target of therapy. The percentage of patients with RA achieving clinical remission has improved markedly compared with a few decades ago. The optimum outcome is to induce remission sufficiently profound so that therapy can be stopped, without flare, that is drug-free remission, which is effectively cure. Limitations of the tools used to measure remission, the outcome of tapering therapy, and new approaches to achieve successful drug cessation are described. Overall, this article reviews progress towards meeting the unmet needs of prevention/cure.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
- Anti-Citrullinated Protein Antibodies in Patients with Rheumatoid Arthritis: Biological Effects and Mechanisms of Immunopathogenesis.
Wu CY, Yang HY, Lai JH. Wu CY, et al. Int J Mol Sci. 2020 Jun 4;21(11):4015. doi: 10.3390/ijms21114015. Int J Mol Sci. 2020. PMID: 32512739 Free PMC article. Review. - Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM, Burgers LE, Toes RE, van der Helm-van Mil A. Boeters DM, et al. Ann Rheum Dis. 2019 Nov;78(11):1497-1504. doi: 10.1136/annrheumdis-2018-214868. Epub 2019 Aug 14. Ann Rheum Dis. 2019. PMID: 31413004 Free PMC article. - The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis.
Petrovská N, Prajzlerová K, Vencovský J, Šenolt L, Filková M. Petrovská N, et al. Autoimmun Rev. 2021 May;20(5):102797. doi: 10.1016/j.autrev.2021.102797. Epub 2021 Mar 18. Autoimmun Rev. 2021. PMID: 33746022 Review. - Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention.
Deane KD. Deane KD. Curr Rheumatol Rep. 2018 Jun 26;20(8):50. doi: 10.1007/s11926-018-0754-0. Curr Rheumatol Rep. 2018. PMID: 29946747 Review. - EULAR definition of "arthralgia suspicious for progression to rheumatoid arthritis" in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound.
Ruta S, Prado ES, Chichande JT, Ruta A, Salvatori F, Magri S, Salinas RG. Ruta S, et al. Clin Rheumatol. 2020 May;39(5):1493-1499. doi: 10.1007/s10067-019-04855-0. Epub 2020 Jan 13. Clin Rheumatol. 2020. PMID: 31933033
Cited by
- The Role of Musculoskeletal Ultrasound in the Rheumatoid Arthritis Continuum.
Di Matteo A, Mankia K, Azukizawa M, Wakefield RJ. Di Matteo A, et al. Curr Rheumatol Rep. 2020 Jun 19;22(8):41. doi: 10.1007/s11926-020-00911-w. Curr Rheumatol Rep. 2020. PMID: 32562012 Free PMC article. Review. - Effects of omega-3 supplementation on lipid metabolism, inflammation, and disease activity in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Wang W, Xu Y, Zhou J, Zang Y. Wang W, et al. Clin Rheumatol. 2024 Aug;43(8):2479-2488. doi: 10.1007/s10067-024-07040-0. Epub 2024 Jun 26. Clin Rheumatol. 2024. PMID: 38922552 - When and how should we use imaging in individuals at risk of rheumatoid arthritis?
Harnden K, Di Matteo A, Mankia K. Harnden K, et al. Front Med (Lausanne). 2022 Nov 23;9:1058510. doi: 10.3389/fmed.2022.1058510. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36507546 Free PMC article. Review. - Ultrasound subclinical synovitis in anti-CCP-positive at-risk individuals with musculoskeletal symptoms: an important and predictable stage in the rheumatoid arthritis continuum.
Di Matteo A, Duquenne L, Cipolletta E, Nam JL, Garcia-Montoya L, Wakefield RJ, Mahler M, Mankia K, Emery P. Di Matteo A, et al. Rheumatology (Oxford). 2022 Aug 3;61(8):3192-3200. doi: 10.1093/rheumatology/keab862. Rheumatology (Oxford). 2022. PMID: 34849610 Free PMC article. - Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study.
Garcia-Montoya L, Nam JL, Duquenne L, Villota-Eraso C, Di Matteo A, Hartley C, Mankia K, Emery P. Garcia-Montoya L, et al. Arthritis Res Ther. 2022 Jan 18;24(1):26. doi: 10.1186/s13075-022-02717-w. Arthritis Res Ther. 2022. PMID: 35042555 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical